Fludrocortisone
- Generic Name
- Fludrocortisone
- Brand Names
- Florinef
- Drug Type
- Small Molecule
- Chemical Formula
- C21H29FO5
- CAS Number
- 127-31-1
- Unique Ingredient Identifier
- U0476M545B
- Background
Fludrocortisone is a synthetic mineralocorticoid used in conjunction with hydrocortisone to replace missing endogenous corticosteroids in patients with adrenal insufficiency. It is functionally similar to aldosterone, the body's primary endogenous mineralocorticoid, and is structurally analogous to cortisol, differing only by a fluorine atom at the 9-positio...
- Indication
Fludrocortisone is indicated as partial replacement therapy for primary or secondary adrenocortical insufficiency in Addison's disease. It is also indicated for the treatment of salt-losing androgenital syndrome.
- Associated Conditions
- Otitis Externa, Otitis Media (OM), Primary adrenocortical insufficiency, Secondary adrenocortical insufficiency, Salt-losing Androgenital syndrome
- Associated Therapies
- -
Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Santhera Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT06649409
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT06633419
- Locations
- 🇺🇸
Celerion ( Site 0001), Tempe, Arizona, United States
A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)
- Conditions
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 8
- Registration Number
- NCT06566989
- Locations
- 🇬🇧
Quotient Sciences ( Site 0001), Nottingham, Nottinghamshire, United Kingdom
A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)
- Conditions
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT06554639
- Locations
- 🇺🇸
Celerion ( Site 0001), Tempe, Arizona, United States
FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage
- Conditions
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- The George Institute
- Target Recruit Count
- 524
- Registration Number
- NCT06409364
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 220
- Registration Number
- NCT06353386
- Locations
- 🇨🇦
Centre Hospitalier de l'Université de Montréal ( Site 0200), Montréal, Quebec, Canada
🇵🇱Uniwersyteckie Centrum Kliniczne ( Site 1405), Gdansk, Pomorskie, Poland
🇬🇧Addenbrooke's Hospital ( Site 1902), Cambridge, Cambridgeshire, United Kingdom
A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT06136598
- Locations
- 🇨🇳
Peking University First Hospital-Urology ( Site 0001), Beijing, Beijing, China
🇨🇳Tongji Hospital Tongji Medical,Science & Technology ( Site 0002), Wuhan, Hubei, China
🇨🇳Sun Yat-sen University Cancer Center-Neurosurgery department ( Site 0003), Guangzhou, Guangdong, China
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1200
- Registration Number
- NCT06136624
- Locations
- 🇺🇸
Stanford Cancer Center ( Site 0036), Palo Alto, California, United States
🇳🇱Amsterdam UMC, locatie VUmc ( Site 1156), Amsterdam, Noord-Holland, Netherlands
🇵🇱Zachodniopomorskie Centrum Onkologii ( Site 1311), Szczecin, Zachodniopomorskie, Poland
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1500
- Registration Number
- NCT06136650
- Locations
- 🇺🇸
Stanford Cancer Center ( Site 0036), Palo Alto, California, United States
🇸🇬National University Hospital ( Site 1201), Singapore, Central Singapore, Singapore
🇹🇭Chulalongkorn University ( Site 1355), Bangkok, Krung Thep Maha Nakhon, Thailand
A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)
- Conditions
- Interventions
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6
- Registration Number
- NCT06104449
- Locations
- 🇯🇵
Yokohama City University Medical Center ( Site 0002), Yokohama, Kanagawa, Japan
🇯🇵National Cancer Center Hospital East ( Site 0001), Kashiwa, Chiba, Japan
🇯🇵Toho University Sakura Medical Center ( Site 0003), Sakura, Chiba, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.